Overweight or Obesity Clinical Trials in Phoenix, Arizona

4 studies are recruiting for overweight or obesity in Phoenix, Arizona right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)

   The main purpose of this study is to assess the effectiveness of adding tirzepatide to ixekizumab therapy in standard clinical practice in participants with active PsA and obesity or overweight with at least 1 weight-related comorbidity. The study will last up to 12 months.

   Stage

   Phase 4

   Ages

   18 and older

   Site

   AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Phoenix PV, Phoenix, Arizona

   Locations

   55 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT06864026 on ClinicalTrials.gov

2. Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight

   The YDAN master protocol will support two independent studies, J3R-MC-YOA1 and J3R-MC-YOA2. Each study will investigate how well and safely Eloralintide (LY3841136) works in adults with obesity or overweight who have osteoarthritis (OA) of the knee with pain. Participation in the study will last ab…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Elite Clinical Studies, LLC, Phoenix, Arizona

   Locations

   152 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT07353931 on ClinicalTrials.gov

3. A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)

   The main purpose of this study is to assess the effectiveness of adding tirzepatide to ixekizumab therapy in standard clinical practice in participants with moderate-to-severe plaque PsO and obesity or overweight with at least 1 weight-related comorbidity. The study will last up to 12 months.

   Stage

   Phase 4

   Ages

   18 and older

   Site

   Medical Dermatology Specialists, Phoenix, Arizona

   Locations

   39 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT06857942 on ClinicalTrials.gov

4. Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation

   The goal of the study is to learn how a weight loss medication called semaglutide, which is used to treat obesity, in addition to standard AF treatment might affect AF, atrial fibrillation severity, and whether it changes the risk of atrial fibrillation recurring after standard AF treatments.

   Stage

   Phase 3

   Ages

   18 to 75

   Site

   The University of Arizona College of Medicine- Phoenix, Phoenix, Arizona

   Locations

   2 in total

   Run by

   University of Chicago

   See if you can join NCT06499857 on ClinicalTrials.gov